The biotechnology firm, BioCryst Pharmaceuticals, Inc., located in the United States, focuses on developing innovative small-molecule drugs from multiple scientific disciplines to combat infectious and inflammatory diseases. With a Risk Rating Score of 25.1, the company is considered to have a medium risk. BioCryst's products and candidates target various therapeutic areas such as acute uncomplicated influenza, hereditary angioedema, and oncology. Using ESG principles, the company aims to ensure environmental protection, sustainability, and effective governance in its operations.